Celimmune licenses anti-IL-15 monoclonal antibody from Amgen Celimmune LLC, a clinical development-stage immunotherapy company centered on treating and preventing autoimmune diseases, today that it has licensed a Stage 2-stage announced, anti-IL-15 monoclonal antibody from Amgen . Under the provisions of the exclusive license agreement, Celimmune gets the rights to develop, produce and commercialize AMG 714 on a worldwide basis excluding Japan. Concurrently, Amgen provides been granted an exclusive substitute for reacquire AMG 714, upon completion of additional medical studies letadalafil.net . Financial terms of the agreements are not being disclosed.
Related StoriesAnalysis of high-throughput sequencing data reveals new genes linked to chronic lymphocytic leukemiaNew study reveals that social factors may impact critical aspects of health in AML patientsPenn study forms basis for brand-new treatment methods for Sezary syndromeIn component among the study, sufferers received an initial cycle of subcutaneous azacitidine . Thereafter, they were designated to different doses of oral azacitidine for the first seven days of repeated 28-day schedules. Partly two, patients were assigned to 1 of four dosing schedules of oral azacitidine: 300 mg daily or 200 mg two times per day time, each for either 14 or 21 times of every 28-day cycle.